SecBot SecBot
Insider Cluster (3 insiders) ·Filed May 18, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago
Insider cluster: 3 insiders, $1.0M total
Actionable Insight • Neutral

The insider sales are routine cashless-exercise dispositions at trivial dollar amounts relative to market cap. No material sell signal. The Q1 earnings decline is the more relevant fundamental story, watch for any further deterioration in Tyvaso franchise pricing/volume trends or the expected commercial supply agreement charge. The upcoming ralinepag DPI Phase 2 readout is the next key catalyst.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$563.96
T+0 close · May 18, 2026 · via day close
Latest settled
−11.44%
T+60 · $499.42
Vs SPY
−17.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $563.96entry
  2. T+1 · 6mo ago −0.41%α −1.45% · $561.64
  3. T+5 · 6mo ago +0.67%α −1.63% · $567.74
  4. T+20 · 5mo ago −2.78%α −5.04% · $548.27
  5. T+60 · 3mo ago −11.44%α −17.46% · $499.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Martine Rothblatt, CFO James Edgemond, and Director Nilda Mesa sold a total of ~$1.03M in UTHR shares over the past week, overwhelmingly driven by CEO Rothblatt's option exercises and same-day sales. The sales follow Q1 earnings (May 6) showing a 2% YoY revenue decline and 15% net income drop, a negative report that could naturally trigger normal portfolio rebalancing. At just ~0.004% of UTHR's $24.1B market cap, the cluster is economically trivial and entirely consistent with routine option-cash exercises, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.0M
Insiders
3

Key Facts

  • Three insiders (CEO, CFO, Director) sold shares in aggregate sold only ~$1.03M in open-market sales, just 0.004% of UTHR's $24.1B market cap
  • CEO Martine Rothblatt accounted for ~$1.79M of the $1.98M in gross open-market sales volume; her sales were all same-day dispositions following option exercises at exercise prices of $146.03 or $0, consistent with routine cashless exercises
  • CFO Edgemond sold a token 80 shares ($45K) and Director Mesa sold 258 shares ($150K), immaterial amounts
  • COO Michael Benkowitz gifted 11,728 shares ($0), non-economic event
  • Q1 2026 revenues fell 2% YoY to $781.5M and net income fell 15% to $274.9M; Tyvaso DPI grew 9% but Nebulized Tyvaso declined 22%
  • Cluster occurred 12 days after earnings, well within the normal trading window after a blackout lift

Financial Impact

$1.03M in open-market sales, ~0.004% of market cap, negligible economic impact

insider_holdings

Risk Factors

  • Q1 revenue decline could continue into pressure on growth expectations for Tyvaso franchise
  • Commercial supply agreement reserve of $26.8M may recur if inventory levels remain elevated
  • Competitive dynamics in inhaled prostacyclins remain dynamic per management's own language

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1779142716684

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026